SecBot SecBot
SECBOTREPLAY Home › Report › UTHR

UTHR · Insider sales post-Q3 earnings

UNITED THERAPEUTICS Corp · CLUSTER filed Nov 9, 2026 at 17:41 ET

At the news

NEUTRALIMPACT 2/10

CLUSTER filed Nov 9, 2026 at 17:41 ET

CEO Martine Rothblatt and EVP Paul Mahon sold a combined $108K in open-market sales under 10b5-1 plans, following the company's Q3 earnings report that showed revenue above consensus but EPS below due to a $130M in-process R&D charge. The sales are small relative to the $24.1B market cap (0.0004%) and appear to be routine plan-driven transactions, not a signal of deteriorating fundamentals.

  • CEO Rothblatt sold $61K in open-market shares on Nov 6 under a 10b5-1 plan
  • EVP Mahon sold $47K in open-market shares on Nov 5 under a 10b5-1 plan
  • Total insider sales of $108K represent 0.0004% of UTHR's $24.1B market cap
  • Sales occurred 1-2 days after Q3 2026 earnings (revenue $832.5M, +4% YoY, above $781.1M consensus; GAAP EPS $5.71 below $6.04 consensus due to $130M IPR&D charge)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access